Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J. Verschure, Iros Barozzi, Valentina Vircillo, Sung Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci

Research output: Contribution to journalArticle

Abstract

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs). However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5% of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1 amp). Relapsed patients also developed numerous mutations targeting key breast cancer-associated genes, including ESR1 and CYP19A1. Notably, CYP19A1 amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in CYP19A1 amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1 amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.

Original languageEnglish
Pages (from-to)444-450
Number of pages7
JournalNature Genetics
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Aromatase Inhibitors
Estrogen Receptors
Breast Neoplasms
Aromatase
Estrogens
Autocrine Communication
Selective Estrogen Receptor Modulators
Therapeutics
Neoplasm Genes
Recurrence
Mutation
Genes
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. / Magnani, Luca; Frigè, Gianmaria; Gadaleta, Raffaella Maria; Corleone, Giacomo; Fabris, Sonia; Kempe, Hermannus; Verschure, Pernette J.; Barozzi, Iros; Vircillo, Valentina; Hong, Sung Pil; Perone, Ylenia; Saini, Massimo; Trumpp, Andreas; Viale, Giuseppe; Neri, Antonino; Ali, Simak; Colleoni, Marco Angelo; Pruneri, Giancarlo; Minucci, Saverio.

In: Nature Genetics, Vol. 49, No. 3, 01.03.2017, p. 444-450.

Research output: Contribution to journalArticle

Magnani, L, Frigè, G, Gadaleta, RM, Corleone, G, Fabris, S, Kempe, H, Verschure, PJ, Barozzi, I, Vircillo, V, Hong, SP, Perone, Y, Saini, M, Trumpp, A, Viale, G, Neri, A, Ali, S, Colleoni, MA, Pruneri, G & Minucci, S 2017, 'Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer', Nature Genetics, vol. 49, no. 3, pp. 444-450. https://doi.org/10.1038/ng.3773
Magnani, Luca ; Frigè, Gianmaria ; Gadaleta, Raffaella Maria ; Corleone, Giacomo ; Fabris, Sonia ; Kempe, Hermannus ; Verschure, Pernette J. ; Barozzi, Iros ; Vircillo, Valentina ; Hong, Sung Pil ; Perone, Ylenia ; Saini, Massimo ; Trumpp, Andreas ; Viale, Giuseppe ; Neri, Antonino ; Ali, Simak ; Colleoni, Marco Angelo ; Pruneri, Giancarlo ; Minucci, Saverio. / Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. In: Nature Genetics. 2017 ; Vol. 49, No. 3. pp. 444-450.
@article{964844ca9be34e76832cdb28c0916d73,
title = "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer",
abstract = "Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs). However, more than 20{\%} of patients relapse within 10 years and eventually progress to incurable metastatic disease. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5{\%} of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1 amp). Relapsed patients also developed numerous mutations targeting key breast cancer-associated genes, including ESR1 and CYP19A1. Notably, CYP19A1 amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in CYP19A1 amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1 amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.",
author = "Luca Magnani and Gianmaria Frig{\`e} and Gadaleta, {Raffaella Maria} and Giacomo Corleone and Sonia Fabris and Hermannus Kempe and Verschure, {Pernette J.} and Iros Barozzi and Valentina Vircillo and Hong, {Sung Pil} and Ylenia Perone and Massimo Saini and Andreas Trumpp and Giuseppe Viale and Antonino Neri and Simak Ali and Colleoni, {Marco Angelo} and Giancarlo Pruneri and Saverio Minucci",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/ng.3773",
language = "English",
volume = "49",
pages = "444--450",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

AU - Magnani, Luca

AU - Frigè, Gianmaria

AU - Gadaleta, Raffaella Maria

AU - Corleone, Giacomo

AU - Fabris, Sonia

AU - Kempe, Hermannus

AU - Verschure, Pernette J.

AU - Barozzi, Iros

AU - Vircillo, Valentina

AU - Hong, Sung Pil

AU - Perone, Ylenia

AU - Saini, Massimo

AU - Trumpp, Andreas

AU - Viale, Giuseppe

AU - Neri, Antonino

AU - Ali, Simak

AU - Colleoni, Marco Angelo

AU - Pruneri, Giancarlo

AU - Minucci, Saverio

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs). However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5% of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1 amp). Relapsed patients also developed numerous mutations targeting key breast cancer-associated genes, including ESR1 and CYP19A1. Notably, CYP19A1 amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in CYP19A1 amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1 amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.

AB - Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs). However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases. We found that 21.5% of AI-treated, relapsed patients had acquired CYP19A1 (encoding aromatase) amplification (CYP19A1 amp). Relapsed patients also developed numerous mutations targeting key breast cancer-associated genes, including ESR1 and CYP19A1. Notably, CYP19A1 amp cells also emerged in vitro, but only in AI-resistant models. CYP19A1 amplification caused increased aromatase activity and estrogen-independent ERα binding to target genes, resulting in CYP19A1 amp cells showing decreased sensitivity to AI treatment. These data suggest that AI treatment itself selects for acquired CYP19A1 amp and promotes local autocrine estrogen signaling in AI-resistant metastatic patients.

UR - http://www.scopus.com/inward/record.url?scp=85010868129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010868129&partnerID=8YFLogxK

U2 - 10.1038/ng.3773

DO - 10.1038/ng.3773

M3 - Article

AN - SCOPUS:85010868129

VL - 49

SP - 444

EP - 450

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 3

ER -